Identification of novel leukemia associated antigen which may useful for immunotherapy of leukemia patients

1.通过重组表达克隆（SEREX）方法的抗原血清学鉴定已经成功地鉴定了许多引起体液免疫应答的肿瘤抗原。在本研究中，我们定义了一种新的抗原，引起白血病患者的体液免疫反应，并在白血病细胞中过表达。Apg-1可诱导白血病患者产生体液免疫应答，有望成为白血病抗原特异性免疫治疗的新靶点。2.采用体外转录mRNA电穿孔基因转染技术，建立了负载抗原的DC激活的CTL细胞株。然而，我们没有检测到这种活化的T细胞对白血病细胞系的任何细胞毒活性。3.随后，我们通过计算机计算鉴定了Apg-1编码的四个具有HLA-A24结合基序的9聚体肽。其中一种多肽能有效地杀伤同时表达Apg-1和HLA-A_（24）的白血病细胞系。我们的结果提示Apg-1抗原可能是白血病相关抗原之一。

1.Serological identification of antigens by the recombinant expression cloning (SEREX) method has successfully identified many tumor antigens that elicit humoral immune response. In the present study, we defined a novel antigen that elicited humoral immune response in patients with leukemia and that was overexpressed in leukemia cells. Apg-1 can elicit humoral immune responses in leukemia patients and might be potential novel targets for antigen-specific immunotherapy for leukemia.2.Using in vitro transcripted mRNA electroporation gene delivery, we developed CTL line activated by the antigen loading DC. However, we could not detect any cytotoxic activity in this activated T cells for leukemic cell line.3.Thereafter, we identified four 9-mer peptides with HLA-A24-binding motifs encoded by Apg-1 using computer calculation. Of these, one peptide developed efficiently effector cells which lysed leukemic cell line expressing both Apg-1 and HLA-A24.Our results indicate that Apg-1 antigen may be one of leukemia associated antigens.